Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Erik Hack

Showing results (31-40 of 165) with videos related to

Pageof 17
Sort By:
Immunobiology|October 25, 2002
Therapeutic inhibition of the early phase of complement activationAnja Roos, Tamara H Ramwadhdoebé, Alma J Nauta, et al.
Autoimmunity|August 6, 2004
Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cellsBas Zwart, Caroline Ciurana, Irma Rensink, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 17, 2011
Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedemaAnurag Relan, Kamran Bakhtiari, Edwin S van Amersfoort, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedemaColm Farrell, Siobhan Hayes, Anurag Relan, et al.
Thrombosis Research|April 1, 2006
Factor XIII in severe sepsis and septic shockSacha Zeerleder, Verena Schroeder, Bernhard Lämmle, et al.
The Journal of Allergy and Clinical Immunology|May 4, 2020
Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I studyZonne L M Hofman, Chantal C Clark, C Erik Hack, et al.
FEMS Yeast Research|November 5, 2005
Production, purification and characterisation of recombinant Fahsin, a novel antistasin-type proteinase inhibitorEric C de Bruin, Dorina Roem, Ingrid Bulder, et al.
Current Pharmaceutical Design|March 7, 2012
Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destructionAngela Bikker, C Erik Hack, Floris P J G Lafeber, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2016
Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation processZonne L M Hofman, Anurag Relan, Sacha Zeerleder, et al.
Clinical Drug Investigation|March 7, 2013
Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodiesC Erik Hack, Anurag Relan, Aartie Baboeram, et al.
Pageof 17

Showing results (31-40 of 165) with videos related to

Sort By:
Pageof 17
Immunobiology|October 25, 2002
Therapeutic inhibition of the early phase of complement activationAnja Roos, Tamara H Ramwadhdoebé, Alma J Nauta, et al.
Autoimmunity|August 6, 2004
Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cellsBas Zwart, Caroline Ciurana, Irma Rensink, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 17, 2011
Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedemaAnurag Relan, Kamran Bakhtiari, Edwin S van Amersfoort, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedemaColm Farrell, Siobhan Hayes, Anurag Relan, et al.
Thrombosis Research|April 1, 2006
Factor XIII in severe sepsis and septic shockSacha Zeerleder, Verena Schroeder, Bernhard Lämmle, et al.
The Journal of Allergy and Clinical Immunology|May 4, 2020
Detecting oral kallikrein-targeting therapy through triggered contact activation: A phase I studyZonne L M Hofman, Chantal C Clark, C Erik Hack, et al.
FEMS Yeast Research|November 5, 2005
Production, purification and characterisation of recombinant Fahsin, a novel antistasin-type proteinase inhibitorEric C de Bruin, Dorina Roem, Ingrid Bulder, et al.
Current Pharmaceutical Design|March 7, 2012
Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destructionAngela Bikker, C Erik Hack, Floris P J G Lafeber, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2016
Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation processZonne L M Hofman, Anurag Relan, Sacha Zeerleder, et al.
Clinical Drug Investigation|March 7, 2013
Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodiesC Erik Hack, Anurag Relan, Aartie Baboeram, et al.
Pageof 17